Expression of cell proliferation markers in pituitary adenomas - Correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIα

Acta Neurochirurgica

Volumn 146, Issue 8, 2004, Pages 831-838

  Wolfsberger, Stefan ^a,b   Wunderer, J ^a,b   Zachenhofer, I ^b   Czech, T ^b   Bocher Schwarz H G ^b   Hainfellner, J ^a   Knosp, E ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Invasiveness; MIB 1; Pituitary adenoma; Proliferation marker; Topoisomerase II

Indexed keywords

BIOCHEMICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING) A; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CELL PROLIFERATION; COHORT ANALYSIS; DNA STRAND BREAKAGE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLING; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 3543063975     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Abe T, Sanno N, Osamura YR, Matsumoto K (1997) Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien) 139(7): 613-618
2. Abe T, Tara LA, Ludecke DK (1999) Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 45(1): 1-10
3. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379(6562): 225-232
4. Bredel M, Slavc I, Bimer P, Czech T, Haberler C, Strobel T, Wolfsberger S, Budka H, Hainfellner JA (2002) DNA topoisomerase IIalpha expression in optic pathway gliomas of childhood. Eur J Cancer 38(3): 393-400
5. Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11): 1046-1052
6. Cardoso ER, Peterson EW (1984) Pituitary apoplexy: a review. Neurosurgery 14(3): 363-373
7. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7): 2102-2107
8. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138(12): 1449-1455
9. Endl E, Gerdes J (2000) The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257(2): 231-237
10. Fahlbusch R, Buchfelder M (1988) Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien) 92(1-4): 93-99
11. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64: 221-253
12. Fraioli B, Ferrante L, Celli P (1983) Pituitary adenomas with onset during puberty. Features and treatment. J Neurosurg 59(4): 590-595
13. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 8(2): 160-164
14. Gerdes J, Becker MH, Key G, Cattoretti G (1992) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 168(1): 85-86
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4): 1710-1715
16. Hardy J, Vezina JL (1976) Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 15: 261-273
17. Holden JA, Townsend JJ (1999) DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12(12): 1094-1100
18. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4): 674-679
19. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, Nagura H (1997) DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 10(9): 901-907
20. Ito K, Sasano H, Yabuki N, Matsunaga G, Sato S, Kikuchi A, Yajima A, Nagura H (1997) Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium. Mod Pathol 10(4): 289-294
21. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti SL, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2): 103-113
22. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136(1-2): 37-43
23. Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir [Suppl] (Wien) 53: 60-64
24. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25(6): 927-930
25. Knosp E, Kitz K, Steiner E, Matula C (1991) Pituitary adenomas with parasellar invasion. Acta Neurochir [Suppl] (Wien) 53: 65-71
26. Kovacs K, Horvath E, Vidal S (2001) Classification of pituitary adenomas. J Neurooncol 54(2): 121-127
27. Kovacs K, Scheithauer B, Horvath E, Lloyd RV (1999) The adenohypophysis. In: Solcia E, Klöppel G, Sobin LH (eds) The World Health Organization Classification of Endocrine Tumours. Springer, Berlin Heidelberg New York Tokyo, pp 15-28 and 75-90
28. Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67(6): 803-806
29. Li H, Byeon IJ, Ju Y, Tsai MD (2004) Structure of human Ki67 FHA domain and its binding to a phosphoprotein fragment from hNIFK reveal unique recognition sites and new views to the structural basis of FHA domain functions. J Mol Biol 335(1): 371-381
30. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47(6): 1313-1318
31. Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1(1): 12
32. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52(2): 107-111
33. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2): 195-208
34. Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41(3): 359-364
35. Pegolo G, Buckwalter JG, Weiss MH, Hinton DR (1995) Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Acta Cytol 39(5): 887-892
36. Saeger W, Schreiber S, Ludecke DK (2001) Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas. Endocr Pathol 12(1): 39-47
37. Schaller B (2002) Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study. Pituitary 5(4): 247-253
38. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65(6): 733-744
39. Schneider E, Hsiang YH, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183
40. Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64(3): 402-407
41. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MlB-1 antibody. Neurosurgery 38(1): 99-106
42. Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, Li J, Laws ER Jr (1997) Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72(10): 893-900
43. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW (2002) Topoisomerase Ilalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 15(11): 1205-1212
44. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2(4): 209-214
45. Wolfsberger S, Fischer I, Hoeftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J (2004) Ki-67 immunolabelling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol (in press)
46. Yonezawa K, Tamaki N, Kokunai T (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48(5): 494-500
47. Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141(2): 187-192